Identification of the immune response against tumour antigens in patients with lung adenocarcinoma

Identification of the immune response against tumour antigens in patients with lung adenocarcinoma - XAGE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56899

Enrollment

Registered

2011-02-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenocarcinoma lung cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with suspected or proven lung adenocarcinoma who will undergo endosonograpgy in order to pre-operatively stage the mediastinum for lymph node metastases.

Exclusion criteria

Exclusion criteria: No adenocarcinoma No clinical indication for undergoing endosonography

Design outcomes

Primary

Measure	Time frame
The primary objective of this study is - to assess the presence, type and strength of XAGE-1B-specific cellular immune responses of lung cancer patients in the peripheral blood, mediastinal lymph nodes and the primary tumour. - to assess the expression of the XAGE-1B antigen in the primary lung tumor	—

Secondary

Measure	Time frame
- the presence, type and strength of XAGE-1B-specific cellular immune response in the primary tumour of patients that undergo tumour resection after diagnostic work-up - the presence, type and strength of antigen-specific cellular immune responses against potential other tumour antigens (including p53 and HPV16) in lung adenocarcinoma patients - whether the presence of a specific cellular immune response is associated with a certain type of lung adenocarcinoma patients. - whether chemotherapy enhances the activation of systemically present antigen-specific immune response. - whether there exists a relation between the presence of a specific immune response and clinical outcome of patients with lung adenocarcinoma	—

Measure

Time frame

- the presence, type and strength of XAGE-1B-specific cellular immune response in the primary tumour of patients that undergo tumour resection after diagnostic work-up - the presence, type and strength of antigen-specific cellular immune responses against potential other tumour antigens (including p53 and HPV16) in lung adenocarcinoma patients - whether the presence of a specific cellular immune response is associated with a certain type of lung adenocarcinoma patients. - whether chemotherapy enhances the activation of systemically present antigen-specific immune response. - whether there exists a relation between the presence of a specific immune response and clinical outcome of patients with lung adenocarcinoma

—

Countries

Netherlands

Outcome results